Beginning in mid-February 2008, the 1997-2007 online version of the Science Watch® newsletter, ESI-Topics.com, and in-cites.com, will all be featured together on the redesigned ScienceWatch.com. All previous content from the three sites will be permanently archived, and remain accessible from any existing bookmarks to the archived pages. No new content will be added to this site. Updates and new content (updated biweekly) are available at ScienceWatch.com now.

New Hot Paper Comments

By Yosef Shiloh

ESI Special Topics, July 2004
Citing URL - http://www.esi-topics.com/nhp/2004/july-04-YosefShiloh.html

Yosef Shiloh answers a few questions about this month's new hot paper in the field of Clinical Medicine.


From •>>July 2004

Field: Clinical Medicine
Article Title: ATM and related protein kinases: Safeguarding genome integrity
Authors: Shiloh, Y
Journal: NAT REV CANCER
Volume: 3
Page: 155-168
Year: MAR 2003
* Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.
* Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, David & Inez Myers Lab Genet Res, IL-69978 Tel Aviv, Israel.

ST:  Why do you think your paper is highly cited?


We now understand the chain of events that leads to instantaneous activation of the enormous cellular response to DNA lesions”

This paper is a review, and reviews tend to be highly cited. But there is probably more to it than that. The paper deals with a central subject in biomedical research: the cellular responses to DNA damage. These responses are essential for maintaining the genomic stability and integrity essential for preventing cellular death or malignant transformation. Defects in this system lead to a variety of very severe diseases. Thus, this field is of great interest to basic scientists as well as to clinicians from many areas of medicine.

ST:  Does it describe a new discovery or new methodology that's useful to others?

The paper summarizes several new concepts that have emerged recently in this rapidly evolving field, and sums up the significant advances in our understanding of the complex network of processes that respond to DNA damage. Several of the major players in this response are potential targets for cancer therapy, making this information useful to cancer researchers and oncologists. On the other hand, the degenerative nature of genetic disorders associated with defects in the DNA damage response attracts the attention of investigators and physicians in areas such as neurology, immunology, gerontology, and public health.

ST:  Could you summarize the significance of your paper in layman's terms?

Our genetic material, the DNA, which is contained in the nucleus of every cell of our body, is constantly under attack from physical and chemical agents that cause a variety of DNA lesions. While some of these agents are external, many are formed within the cell as by-products of normal metabolism. A sophisticated system has evolved to respond to these lesions—an intricate network that includes DNA repair machinery and numerous other stress responses that help the cell maintain metabolic equilibrium while its normal life cycle is temporarily halted to allow DNA repair to take place. Defects in this system lead to severe genetic disorders involving tissue degeneration, sensitivity to specific damaging agents, genomic instability, and cancer predisposition. Furthermore, subtle defects in the DNA damage response probably underlie certain chronic diseases, cancer predisposition in the general population, and differences in the pace at which individuals age. Recent progress in our understanding of the DNA damage response has led to the discovery of many of the central players in this system. We now understand the chain of events that leads to instantaneous activation of the enormous cellular response to DNA lesions. This system is turning out to be a prime example of cellular signal transduction.

ST:  How did you become involved in this research?

My involvement in this field stems from my long-term interest in a devastating human genetic disorder called ataxia-telangiectasia (A-T), an interest that began when I was a graduate student some 27 years ago and met a family with A-T. The striking phenotype of the patients led me to make the disease the subject of my Ph.D. thesis and I have remained in A-T research ever since. A-T is caused by a defect in the cellular response to a specific type of DNA lesion—the double-strand break. This is the most critical DNA lesion caused by ionizing radiation. A-T patients suffer from neurodegeneration, immunodeficiency, radiation sensitivity, genomic instability, and cancer predisposition. In 1995, our lab in Tel Aviv identified the defective gene that leads to A-T, and called it ATM (A-T, Mutated). We then shifted gears from molecular genetics to protein chemistry and began studying the ATM protein, the product of the ATM gene, in order to understand the physiological basis of A-T. Work in our lab and many other labs has elucidated the role of the ATM protein as the chief regulator and mobilizer of the cellular responses to DNA double-strand breaks. We now understand how one protein, ATM, can stir such a wide chain of reactions, sometimes in response to very few or even a single double-strand break in the DNA!End

Yosef Shiloh, Ph.D.
Professor of Human Genetics
David and Inez Myers Professor of Cancer Genetics
Department of Human Genetics and Molecular Medicine
Sackler School of Medicine
Tel Aviv University
Tel Aviv, ISRAEL

ESI Special Topics, July 2004
Citing URL - http://www.esi-topics.com/nhp/2004/july-04-YosefShiloh.html

•> Search Special Topics
New Hot Papers Menu || All Topics Menu
New Hot Papers Comments Menu
Help || About || Contact

ScienceWatch.com - Tracking Trends and Perfomance in Basic Research
Go to the new ScienceWatch.com

Write to the Webmaster with questions/comments. Terms of Usage.
The Research Services Group of Thomson Scientific |
(c) 2008 The Thomson Corporation.